Navigation Links
Study Finds Children More Likely to Receive Recommended RSV Medication Doses When Administered Through Specialty Pharmacy
Date:10/20/2011

ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care Pharmacy's (AMCP) Educational Conference in Atlanta, Ga.

Palivizumab (Synagis®) is the only preventive therapy approved for respiratory syncytial virus (RSV), a severe respiratory illness that is the leading cause of bronchiolitis and pneumonia in children under one year of age. The injectable medication is given monthly to infants at high risk, and completing the course of treatment has been shown to decrease costly RSV-related hospitalizations.

Researchers from Prime and two of Prime's Blue Cross and Blue Shield clients used medical and pharmacy claims data from 2,853,925 commercially insured members in the Midwest to identify individuals with a palivizumab claim during the 2009-2010 RSV season. From this, researchers determined 445 members met the analytic criteria and 325 members utilized a specialty pharmacy – a pharmacy that includes access and support for drugs that have high acquisition costs, are difficult to manage, and present reimbursement challenges – for all doses fulfilled.

The analysis found 83.4 percent of infants and children who obtained their palivizumab from a specialty pharmacy received the recommended doses, compared to 65.8 percent who received their medication from a non-specialty pharmacy.

"RSV is a serious illness for infants and children and receiving the proper dose of palivizumab can keep children healthy and prevent unnecessary hospitalizations," said Patrick Gleason, PharmD, director of clinical outcomes assessment for Prime. "This study emphasizes how specialty pharmacies can help improve patient compliance and treatment course completion."  

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds New Blood Thinning Medication, Pradaxa®, Comes at High Cost
2. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
3. Study Sheds Light on Young Suburban Heroin Users
4. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
5. New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications
6. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
7. Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
8. Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector
9. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
10. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
11. Study Shows That Roches Investigational Drug for Alzheimers Disease Removes Amyloid Plaques From the Brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):